Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Candel Therapeutics said integrated clinical and biomarker data showed durable local and systemic immune activation after aglatimagene besadenovec in intermediate-risk localized prostate cancer.
The company said the data from its completed aglatimagene besadenovec trial showed sustained immune remodeling more than two years after treatment versus radiotherapy alone.